| Tulare District Hospital Mobile Clinic | |
|
5313 Road 39 Alpaugh CA 93201-0273 | |
| (559) 684-4530 | |
| (559) 686-1157 |
| Full Name | Tulare District Hospital Mobile Clinic |
|---|---|
| Speciality | Clinic/center - Rural Health |
| Location | 5313 Road 39, Alpaugh, California |
| Authorized Official Name and Position | Paul Walker (CEO) |
| Authorized Official Contact | 5596853462 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Tulare District Hospital Mobile Clinic 869 N Cherry St Tulare CA 93274-2207 Ph: (559) 684-4530 | Tulare District Hospital Mobile Clinic 5313 Road 39 Alpaugh CA 93201-0273 Ph: (559) 684-4530 |
| NPI Number | 1841439627 |
|---|---|
| Provider Enumeration Date | 02/18/2009 |
| Last Update Date | 02/27/2015 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841439627 | NPI | - | NPPES |
| ZZT40359F | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QR1300X | Clinic/center - Rural Health | 120000585 (California) | Primary |
News Archive
The outside of a cancer cell is bombarded by signals. They come from the immune system, supporting tissues and other structures. But how do those signals impact cancer?
Tooth loss may predict the development of dementia late in life, according to a study by University of Kentucky researchers.
Pfizer Inc. today announced that its board of directors authorized a new share repurchase program of up to $5 billion of its common stock. This is in addition to approximately $4 billion of authorization remaining under its current repurchase program and increases the company's total repurchase authorization to $9 billion.
Sexual activity declines in the year after heart attack for patients who don't get instructions from their doctors about when it's safe to resume sex, researchers reported at the American Heart Association's 11th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
› Verified 7 days ago